(1 - 19 von 26
)
Development of targeted SARS-CoV-2 antivirals
www.bionity.com
WebNov 10, · Eisbach’s CEO, Dr. Adrian Schomburg, commented: “Our team is grateful to receive state support for the development of our drug candidates. The biotech scene in …
VNRX: Q Financial and Business Update – CEO Money from WFN1
wfn1.com
May 19, · From this strategic business collaboration, Volition is able to leverage the extensive expertise of Dr. Adrian Schomburg while combining the cost benefits of inhouse manufacturing. Since the beginning of the year, Volition’s team has been undergoing intensive training with Octamer’s team. The firm plans to produce histones and DNA templates ...
VolitionRx Completes Acquisition of Octamer GmbH - 富途牛牛news.futunn.com › post
news.futunn.com
Regarding the transaction, Dr. Adrian Schomburg, Founder and CEO of Octamer said, "I believe that the progress that Volition has made to date on nucleosomes ...
VolitionRx closes €650,000 acquisition of Octamer | S&P Global ...www.spglobal.com › news-insights › trending
www.spglobal.com
· The acquisition includes onsite training for Volition's Belgian scientists and a consultation arrangement with Adrian Schomburg, founder and CEO ...
sortiert nach Relevanz / Datum